Does this mean these medicines cause dementia?

No. Most evidence here is observational, which can show an association but cannot prove a simple cause for every person. The link is still worth discussing because some medicines can affect alertness, memory, delirium risk, falls, or total medication burden.

Which group has the strongest evidence?

Strong anticholinergic medicines have one of the clearest signals, especially when cumulative exposure is high over time. This group includes some older antihistamines, certain antidepressants, bladder antimuscarinics, and other strongly anticholinergic medicines.

Should I stop a medicine if it appears on this list?

No. Do not make abrupt changes on your own. Some medicines need careful clinical planning, and the reason you take them may be important. Use the list to ask a doctor or pharmacist for a medication review.

Are over-the-counter sleep or allergy products part of the concern?

Yes, some over-the-counter sleep, cold, motion-sickness, and allergy products contain first-generation antihistamines with strong anticholinergic effects. Bring nonprescription products to the medication review too, not just prescriptions.

What should I bring to an appointment?

Bring a current list or the actual containers for prescriptions, over-the-counter products, supplements, and medicines used only occasionally. Ask whether any have anticholinergic or sedating effects and whether each one still has a clear purpose.

8 Medication Types Linked to Dementia Risk

Medication organizer, pill bottles, glasses, and a notepad on a kitchen table. | lilicooks.com

The direct answer: the medication groups most often discussed in dementia-risk research include strong anticholinergic antihistamines, anticholinergic antidepressants, bladder antimuscarinics, anticholinergic Parkinson-type medicines, benzodiazepines, Z-drug sleep medicines, antipsychotics, and opioids. This does not mean any one of these medicines automatically causes dementia. It means the link is important enough to review thoughtfully, especially for older adults, people with memory changes, and anyone taking several central nervous system or anticholinergic medicines at the same time.

Why this link deserves nuance

Medication headlines can sound sharper than the science. Dementia usually develops over years, and the reasons differ from person to person. Observational studies can find that people who use a medicine are more likely to receive a dementia diagnosis later, but that pattern can reflect many things: the medicine itself, the condition behind the prescription, frailty, sleep disruption, pain, depression, or early symptoms that appeared before dementia was recognized. That is why the practical question is not, “Is this pill dangerous for everyone?” A better question is, “Does this medicine still fit this person’s current risks, goals, and safer options?”

The strongest signal in the evidence is cumulative anticholinergic burden. Anticholinergic medicines block acetylcholine, a chemical messenger involved in attention, memory, urination, gut movement, secretions, and other body functions. In a JAMA Internal Medicine prospective cohort of adults age 65 and older, higher 10-year cumulative use of strong anticholinergic medicines was associated with higher incident dementia risk; the study listed common exposure classes including antihistamines, antidepressants, bladder antimuscarinics, and other strong anticholinergics https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2091745.

The eight groups worth reviewing are:

First-generation antihistamines, such as diphenhydramine, doxylamine, chlorpheniramine, hydroxyzine, promethazine, and meclizine.
Antidepressants with strong anticholinergic activity, including amitriptyline, imipramine, nortriptyline, doxepin above very low amounts, and paroxetine.
Bladder antimuscarinics, including medicines used for urgency or overactive bladder symptoms.
Anticholinergic Parkinson-type or spasm medicines, such as benztropine, trihexyphenidyl, and some gut antispasmodics.
Benzodiazepines, including alprazolam, clonazepam, diazepam, lorazepam, oxazepam, and temazepam.
Z-drug sleep medicines, including zolpidem, zaleplon, and eszopiclone.
Antipsychotics, especially chronic or persistent use in people who already have dementia or cognitive impairment.
Opioids, where dementia findings are more mixed and may be influenced by pain, overall health, and frailty.

A pharmacist and older adult reviewing several medicines together at a counter. | lilicooks.com

1 to 4: strong anticholinergic medicines

The American Geriatrics Society 2023 Beers Criteria, a widely used reference for medication safety in older adults, flags first-generation antihistamines as highly anticholinergic and says cumulative exposure to anticholinergic medicines is associated with increased risk of falls, delirium, and dementia. It also lists strong anticholinergic antidepressants and certain anticholinergic Parkinson-type medicines as generally avoidable in many older adults, while emphasizing that decisions should support shared clinical judgment https://agsjournals.onlinelibrary.wiley.com/doi/epdf/10.1111/jgs.18372.

First-generation antihistamines are easy to overlook because some are sold over the counter and appear in sleep, cold, allergy, motion-sickness, and nausea products. “Over the counter” does not mean “low brain effect,” especially for older adults. The same medicine may show up in more than one product, so a person might build anticholinergic burden without realizing it. This is one reason a brown-bag review, where every prescription, nonprescription product, vitamin, and supplement is placed on the table for a pharmacist or clinician to check, can be more useful than relying on memory.

Anticholinergic antidepressants and bladder medicines deserve a different kind of care. They may have been started for real symptoms that affect daily life, sleep, confidence, or mood. The concern is not that everyone should abandon them. The concern is that a medicine started years ago may keep running in the background after circumstances have changed. A clinician can check whether the original reason still applies, whether the current benefit is clear, whether side effects such as confusion, constipation, dry mouth, dizziness, or blurred vision are showing up, and whether the total anticholinergic load is higher than it needs to be.

5 and 6: benzodiazepines and Z-drug sleep medicines

Benzodiazepines are often used for anxiety, panic symptoms, muscle spasm, seizures, procedures, and sleep, depending on the specific medicine and situation. The dementia evidence has not all pointed in the same direction. One BMJ prospective population-based study found that new benzodiazepine use was associated with increased dementia risk during follow-up https://pmc.ncbi.nlm.nih.gov/articles/PMC3460255/. Other research has raised concerns about reverse causation, meaning insomnia, anxiety, or mood symptoms may sometimes be early features of a condition that is later recognized as dementia rather than a simple effect of the medicine.

The Beers Criteria still recommends caution in older adults because benzodiazepines can increase cognitive impairment, delirium, falls, fractures, and motor vehicle crash risk. Z-drug sleep medicines were developed separately from benzodiazepines, but the Beers Criteria says they have similar adverse events in older adults, including delirium, falls, fractures, emergency visits, hospitalizations, and motor vehicle crashes. A systematic review of non-benzodiazepine hypnotics found limited and mixed cognitive evidence; one included study found high cumulative zolpidem exposure associated with Alzheimer’s disease, while other findings were weaker or not significant after adjustment https://pmc.ncbi.nlm.nih.gov/articles/PMC7810183/.

A simple illustration of a brain beside grouped medicine shapes. | lilicooks.com

7: antipsychotics require a narrow, careful conversation

Antipsychotics are a broad group, and their risk-benefit discussion depends heavily on why they are being used. They may be part of psychiatric care, short-term hospital care, or crisis planning. They may also be used in people living with dementia when distress, agitation, hallucinations, or danger to self or others becomes difficult to manage. The Beers Criteria warns that chronic or persistent as-needed antipsychotic use should generally be avoided in dementia or cognitive impairment because of adverse central nervous system effects; it also notes increased stroke risk, greater rate of cognitive decline, and mortality in people with dementia. That warning is about careful use, not blame.

The practical takeaway is that antipsychotics should not drift into long-term background use without regular review. Families may notice that a medicine helped during a crisis, then months pass and no one revisits whether the same plan is still needed. A review can ask what symptom the medicine is meant to address, whether the target symptom is still present, what non-drug supports are in place, what side effects have appeared, and how often the plan should be reassessed. Any change needs clinical supervision because abrupt changes can be unsafe or destabilizing.

8: opioids and the problem of confounding by pain

Opioids are linked to sedation, delirium, falls, constipation, and dependence concerns, but dementia-specific research is more complicated. In a prospective cohort study of adults age 65 and older, people with the heaviest cumulative opioid exposure had slightly higher dementia risk than those with little or no use, but the authors found little evidence of long-term cognitive harm specific to opioids and noted that chronic pain or residual confounding might explain part of the finding https://pmc.ncbi.nlm.nih.gov/articles/PMC4776316/. That distinction matters: pain itself can affect sleep, mood, movement, attention, and daily function, so the medicine is not the only possible explanation.

For readers, this means opioids belong on a medication-review list, especially when combined with benzodiazepines, Z-drugs, gabapentinoids, alcohol, or other sedating medicines. It does not mean someone should suddenly stop an opioid or endure severe pain without support. The safer path is to ask the prescribing clinician what the current goal is, whether the benefit is still clear, whether side effects are appearing, and whether the whole plan still fits the person’s function, safety, and quality of life.

How to prepare for a safer medication review

The National Institute on Aging advises older adults to keep an updated list of prescription medicines, over-the-counter products, vitamins, supplements, and infrequently used medicines, and to talk with a doctor or pharmacist before starting or stopping medicines https://www.nia.nih.gov/health/medicines-and-medication-management/taking-medicines-safely-you-age. For this topic, the most useful appointment is specific. Bring the actual bottles or a complete list, then ask the clinician to check anticholinergic burden, sedating combinations, duplicate ingredients, fall risk, new confusion, sleepiness, constipation, urinary problems, and whether each medicine still has a clear purpose.

Useful questions include: “Could any of these affect memory or alertness?” “Are any of these first-generation antihistamines or strong anticholinergics?” “Do any of these overlap in sedating effects?” “Is there a reason this medicine is still the best fit for me now?” “What symptoms should we track before changing anything?” These questions keep the discussion practical. They also avoid the two common mistakes: ignoring a possible medication contribution to cognitive symptoms, or reacting to a scary headline by making abrupt changes without a plan.

A blank checklist, pill organizer, and magnifying glass arranged on a table. | lilicooks.com

The cautious takeaway

The clearest message is not that every medication on this list is automatically harmful. The message is that anticholinergic burden and sedating medicine combinations deserve regular attention, especially after age 65, after a fall, after a new memory concern, after a hospital stay, or when several prescribers are involved. The evidence is strongest for strong anticholinergic exposure, clinically important for benzodiazepines and Z-drugs because of cognitive and safety effects, and more context-dependent for antipsychotics and opioids. A good medication review is not about fear; it is about making sure the current list still matches the person in front of the clinician today.

Wrap-Up

Several medication groups have been linked with dementia risk, delirium, or cognitive decline, but the evidence is not equal across groups. Strong anticholinergic medicines have the clearest long-term signal, while benzodiazepines, Z-drugs, antipsychotics, and opioids require careful context. The safest response is a clinician-led medication review that weighs current benefit, side effects, total burden, and personal goals.

Frequently Asked Questions

→ Does this mean these medicines cause dementia?: No. Most evidence here is observational, which can show an association but cannot prove a simple cause for every person. The link is still worth discussing because some medicines can affect alertness, memory, delirium risk, falls, or total medication burden.
→ Which group has the strongest evidence?: Strong anticholinergic medicines have one of the clearest signals, especially when cumulative exposure is high over time. This group includes some older antihistamines, certain antidepressants, bladder antimuscarinics, and other strongly anticholinergic medicines.
→ Should I stop a medicine if it appears on this list?: No. Do not make abrupt changes on your own. Some medicines need careful clinical planning, and the reason you take them may be important. Use the list to ask a doctor or pharmacist for a medication review.
→ Are over-the-counter sleep or allergy products part of the concern?: Yes, some over-the-counter sleep, cold, motion-sickness, and allergy products contain first-generation antihistamines with strong anticholinergic effects. Bring nonprescription products to the medication review too, not just prescriptions.
→ What should I bring to an appointment?: Bring a current list or the actual containers for prescriptions, over-the-counter products, supplements, and medicines used only occasionally. Ask whether any have anticholinergic or sedating effects and whether each one still has a clear purpose.

References

This content was developed and refined using reliable sources.